MyFinsight
Home
Blog
About
Proceeds from sale of
common stock through...
$24,250K
Proceeds from option
exercises
$31K
(-93.70%↓ Y/Y)
Net cash provided by
financing activities
$23,982K
(53.99%↑ Y/Y)
Canceled cashflow
$299K
Net increase
(decrease) in cash, cash...
$6,731K
(442.20%↑ Y/Y)
Canceled cashflow
$17,251K
Proceeds from issuance of
common stock in...
-$299K
Change in fair value of
warrant liabilities
$12,278K
(159.68%↑ Y/Y)
Accrued expenses
$3,512K
(382.54%↑ Y/Y)
Non-cash stock
compensation expense
$2,858K
(109.53%↑ Y/Y)
Accounts payable
$2,384K
(57.57%↑ Y/Y)
Accretion of debt discount
$316K
(315.79%↑ Y/Y)
Prepaid expenses and
other current assets
-$192K
(-110.84%↓ Y/Y)
Depreciation expense
$171K
(-64.89%↓ Y/Y)
Non-cash lease expense
$94K
(-37.75%↓ Y/Y)
Non-cash interest
expense
$40K
(-42.03%↓ Y/Y)
Other assets
-$10K
(44.44%↑ Y/Y)
Net cash used in
operating activities
-$17,182K
(1.86%↑ Y/Y)
Net cash used in
investing activities
-$69K
(-102.94%↓ Y/Y)
Canceled cashflow
$21,855K
Net income (loss)
-$38,905K
(-1606.19%↓ Y/Y)
Purchase of fixed assets
$69K
(102.94%↑ Y/Y)
Lease liability
-$110K
(60.00%↑ Y/Y)
Deferred income
-$22K
Back
Back
Cash Flow
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)
source: myfinsight.com